Biotech Growth Trust notes Esperion acquisition agreement

BIOG

Biotech Growth Trust plc (LON:BIOG) has noted the announcement on Friday, 1 May 2026 that ARCHIMED has entered into an agreement to acquire BIOG portfolio company, Esperion Therapeutics for approximately $1 billion, or $3.16 per share, in cash, representing a 58% premium to Esperion’s closing price on Thursday, 30 April 2026.   The offer also includes an additional $100 million in contingent value right payments which are based on Esperion products achieving certain sales milestones; if met, the aggregate purchase price would total $1.1 billion.

Esperion is a US-based commercial biopharmaceutical company focused on drugs targeting cardiovascular disease.   Its lead drugs are oral therapies to lower cholesterol.

The Company’s holding in Esperion represented 2.5% of the Company’s net asset value (NAV) at the time of the announcement. The transaction will be reflected in the Company’s NAV as at close of business on 1 May 2026, which will be announced on Tuesday, 5 May 2026.

This follows on from recent acquisitions of portfolio companies Avidity Biosciences, Cidara Therapeutics, Amicus Therapeutics, Apellis Pharmaceuticals and KalVista Pharmaceuticals.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Biotech Growth Trust shares rise 22.9% as five portfolio companies agree takeovers

Biotech Growth Trust recorded a 22.9% total return on its share price in the six months to September 2026,...

Biotech Growth Trust reports 16.5% annual share price return as NAV rises 16%

Biotech Growth Trust reported a 16.5% one-year total return on its share price and a 16.0% increase in NAV...

Cancer research advances bring new treatment options and improve patient outcomes

Advances in cancer research are expanding treatment options, improving early detection and developing more personalised approaches....

Drug development continues to create opportunities for medical innovation

The development of new medicines combines scientific research, clinical trials and regulatory review to bring potential treatments closer to...

The Biotech Growth Trust: Recent Sector Weakness Could Present an Opportunity, Says Kepler Partners

The Biotech Growth Trust could benefit from renewed pharmaceutical acquisitions and biotechnology innovation, according to Kepler Partners research....

Biotech Growth Trust positioned to benefit from sector recovery: Kepler

Kepler research highlights the potential for Biotech Growth Trust (BIOG) to benefit from a recovery in biotech stocks, supported...

Search